SALES WORLDWIDE
$7.3B

SALES PERFORMANCE ACROSS ABBOTT
$2B DIAGNOSTICS
$1.9B MEDICAL DEVICES
$2.4B DENTAL
$1B PHARMACEUTICALS

FULL-YEAR 2020 EPS GUIDANCE* at least $3.25
ADJUSTED DILUTED EARNINGS PER SHARE

LAUNCH IN GLOBAL COVID-19 TESTING
- 5 NEW COVID-19 TESTS LAUNCHED
- 40% COVID-19 TESTS SOLD WORLDWIDE

MORE TESTS IN THE PIPELINE TO HELP TEST AS MANY PEOPLE AS POSSIBLE

STRENGTH IN OUR DIVERSESIFIED BUSINESS

Diagnostics
SALES UP 7%

- Abbott Diagnostics won CE mark for Covidiag SARS-CoV-2 Rapid Antigen Test with high sensitivity and specificity
- Achieved world’s first CE mark for COVID-19 test, bringing innovatively high-throughput, highly sensitive assay

FreeStyle Libre
SALES UP 40%

- Announced U.S. FDA clearance of FreeStyle Libre 14+, an advanced continuous glucose monitoring (CGM) system in adults and children with diabetes, enabling patients to monitor their blood glucose levels on their smartphones worldwide
- Rolled out FreeStyle Libre Flash, enabling patients to monitor their blood glucose levels on their smartphones

Secured Approvals FOR IMPORTANT HEART DEVICES

- Approved by the FDA for the Tycya™ Heated Catheter System, offering high-temperature tissue ablation
- Approved by the FDA for the Morpheus™ Total Mitral Valve System, providing patients with an innovative treatment for mitral valve disease
- Approved by the FDA for the AutoPEG™ System, enabling patients to receive the most accurate and efficient treatment for hepatic diseases

Abbott first established itself as a leader in diagnostics through its work with the first rapid diagnostic test for HIV. Today, our diagnostics business includes a wide range of tests for infectious diseases, cancers, genetic disorders, and more. Our continuous glucose monitoring system, FreeStyle Libre, is revolutionizing diabetes management for millions of people around the world. And every day, we work to advance the development of new technologies that can help improve the lives of people affected by heart disease and other chronic conditions.